AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved ejection fraction (EF).

AHA 2024

Tirzepatide, a prolonged action antagonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptides (GLP-1), has a cardiovascular impact we still need to elucidate. 

This was a randomized, double blind study, 1:1, including patients with EF ≥50% and body mass index (BMI) ≥30. Participants were assigned to tirzepatide (up to 15 mg/week, subcutaneous) or placebo.

Primary end points were 1) cardiovascular mortality or CF worsening, and 2) change in quality of life measured with the Kansas Questionnaire. 

731 patients took part in the study, and were followed up to 104 weeks. The primary outcome occurred in 9.9% of tirzepatide patients vs. 15.3% of the placebo group (HR: 0.62, CI 95%: 0.41–0.95; p = 0.026). When breaking down these results, event reduction was attributed mainly to a lower incidence of CF worsening (HR: 0.54, CI 95%: 0.34–0.85).

Read also: AHA 2024 – BPROAD.

As regards change in quality of life, the tirzepatide group showed significant improvement, with a 6.9 score difference (CI 95%: 3.3–10.6; p < 0.001) vs. placebo patients. Non-compliance rate was 6.3%, attributed mainly to gastrointestinal adverse events. 

Authors’ Conclusion: weekly treatment with tirzepatide showed significant reduction of the combined end point of cardiovascular mortality and CF worsening compared against placebo, in obese patients with preserved ejection fraction. 

Presented by Milton Packer at the Scientific Sessions 2024, American Heart Association, November 2024, Chicago, EEUU.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | FLAVOUR II: Angiography-Derived FFR-Guided vs. IVUS-Guided PCI

Physiological assessment is effective when it comes to decision-making for percutaneous coronary intervention (PCI). However, despite the available evidence, its use remains limited. AngioFFR...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...